Lasinone 2mg Capsule contains Nitisinone, a potent inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase, used primarily in the management of hereditary tyrosinemia type 1 (HT-1). By inhibiting this enzyme, Nitisinone reduces the production of toxic metabolites such as fumarylacetoacetate and succinylacetone, which are responsible for liver and kidney damage in affected patients. Lasinone is indicated for long-term treatment to prevent the progression of liver dysfunction, renal tubular dysfunction, and neurological crises associated with HT-1. The recommended dosage should be individualized based on patient response and monitored through plasma succinylacetone levels and liver function tests. Adverse effects may include elevated plasma tyrosine levels, which necessitate dietary restriction of tyrosine and phenylalanine to minimize complications such as keratitis and skin lesions. Regular ophthalmologic and biochemical monitoring is essential during therapy. Lasinone should be used with caution in patients with pre-existing liver impairment and is contraindicated in individuals with hypersensitivity to Nitisinone or any capsule components. This medication should be administered under specialist supervision, ensuring comprehensive management of HT-1 to improve patient prognosis and quality of life.